Gentian Diagnostics ASA (OSL: GENT)

Market Cap	635.40M
Revenue (ttm)	154.12M
Net Income (ttm)	2.22M
Shares Out	15.42M
EPS (ttm)	0.14
PE Ratio	286.21
Forward PE	40.84
Dividend	n/a
Ex-Dividend Date	n/a

Volume	449
Open	41.20
Previous Close	40.00
Day's Range	41.20 - 41.20
52-Week Range	34.80 - 61.00
Beta	0.57
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 31, 2024

About Gentian Diagnostics ASA

Gentian Diagnostics ASA researches, develops, and produces biochemical reagents for use in medical diagnostics and research worldwide. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric immunoassay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a glomerular filtration rate marker for the diagnosis and therapeutic control of renal function; Gentia...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2001
• Employees: 58
• Stock Exchange: Oslo Børs
• Ticker Symbol: GENT

Financial Performance

In 2023, Gentian Diagnostics ASA's revenue was 142.35 million, an increase of 27.18% compared to the previous year's 111.92 million. Losses were -10.65 million, -54.92% less than in 2022.